CRISPR Therapeutics AG (CRSP) Social Stream



CRISPR Therapeutics AG (CRSP): $124.20

0.58 (+0.47%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CRSP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 486

in industry

Featured Post From StockTwits About CRSP

$CRSP 2days of FED meetings.. accumulate now if you feel no measures for inflation will be taken. quad witch day friday znd we are off. Rare to have these events lined up, take advantage when others are fearful.
Xxiii1800, published June 15, 2021

What Else are CRSP Traders Talking About?


Other tickers frequently mentioned alongside CRSP are NIO, SKLZ and SPCE.

Other Notable StockTweets About CRSP


$CRSP — ALZHEIMER’S — not priced in — nor diabetes — nor etc etc etc. as for ALZHEIMER’s— The actual tests involved mouse and human cells, and a mutation that causes late onset Alzheimer’s disease and breast cancer. In one attempt, they were able to effectively change 58% of the cells without much unintended side effects, while other tests registered as much as 75%. CRSP is the cure 🧬

Pfhizhir, published June 7, 2021

$NIO will only head higher from here. Also I love $CRSP and so does CATHY WOOD.
I have 500 shares of $CRSP. Currently I’m Long on >>> $CRSP $SKLZ & $SPCE 🚀🚀🚀

Just buy NIO, CRSP and SKLZ and you are set to 100%+ gain for 2021. CRSP is a 10* stock in 5 Years 🚀🚀👍🏻 and $NIO will reach $450 in 3 years

ABNB PYPL NTDOY ATVI AMZN IDXX PINS SKLZ LMND CRWD ZM FVRR NVDA MASI NIO DIS PLTR NFLX SIVB LMND SHOP MTCH TOL CRSP... all are for long term🔥🔥🔥

Dollar2728, published May 25, 2021

$CRSP From their April AACR meeting .... (I love the final bullet point!)

http://ir.crisprtx.com/static-files/9ca42ab8-38e2-49d5-8919-1946b163bd35

Conclusions from Preclinical Studies
• We applied CRISPR/Cas9 editing to examine the effects of knocking out the gene function of multiple checkpoint-related genes in CAR-T cells, including both “obvious” choices
such as PD1 and LAG3 where antagonism with antibodies has shown anti-cancer properties in humans and mice, as well as less obvious candidates such as CD70
• Surprisingly, not only did CD70 KO perform better than any of the more obvious checkpoint genes, CD70 KO also provided advantages for CAR-T cells targeting multiple antigens
other than CD70
• In contrast, CAR-T cells with classical checkpoint genes knocked out showed no improved properties. In fact, these knock-outs often proved detrimental to CAR-T function
• We have applied the CD70 KO strategy to our CTX130 program currently in clinical trials for solid and heme malignancies

IwannaRetire, published May 17, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5193 seconds.